120 related articles for article (PubMed ID: 9089425)
1. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist.
Appel S; Kumle A; Hubert M; Duvauchelle T
J Clin Pharmacol; 1997 Mar; 37(3):229-37. PubMed ID: 9089425
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit.
Appel S; Kumle A; Meier R
Clin Pharmacol Ther; 1997 Nov; 62(5):546-55. PubMed ID: 9390111
[TBL] [Abstract][Full Text] [Related]
3. SDZ HTF 919 stimulates canine colonic motility and transit in vivo.
Nguyen A; Camilleri M; Kost LJ; Metzger A; Sarr MG; Hanson RB; Fett SL; Zinsmeister AR
J Pharmacol Exp Ther; 1997 Mar; 280(3):1270-6. PubMed ID: 9067313
[TBL] [Abstract][Full Text] [Related]
4. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.
Appel-Dingemanse S; Lemarechal MO; Kumle A; Hubert M; Legangneux E
Br J Clin Pharmacol; 1999 May; 47(5):483-91. PubMed ID: 10336571
[TBL] [Abstract][Full Text] [Related]
5. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).
Appel-Dingemanse S; Hirschberg Y; Osborne S; Pommier F; McLeod J
Eur J Clin Pharmacol; 2001 Mar; 56(12):889-91. PubMed ID: 11317476
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
Appel-Dingemanse S
Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
[TBL] [Abstract][Full Text] [Related]
7. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
Zhou H; Horowitz A; Ledford PC; Hubert M; Appel-Dingemanse S; Osborne S; McLeod JF
J Clin Pharmacol; 2001 Oct; 41(10):1131-9. PubMed ID: 11583482
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
Shin A; Acosta A; Camilleri M; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765
[TBL] [Abstract][Full Text] [Related]
9. Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects.
Swan SK; Zhou H; Horowitz A; Alladina L; Hubert M; Appel-Dingemanse S; Osborne S; Lambrecht L; McLeod JF
J Clin Pharmacol; 2003 Apr; 43(4):359-64. PubMed ID: 12723456
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
11. Tegaserod.
Scott LJ; Perry CM
Drugs; 1999 Sep; 58(3):491-6; discussion 497-8. PubMed ID: 10493276
[TBL] [Abstract][Full Text] [Related]
12. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine.
Grider JR; Foxx-Orenstein AE; Jin JG
Gastroenterology; 1998 Aug; 115(2):370-80. PubMed ID: 9679042
[TBL] [Abstract][Full Text] [Related]
13. Almotriptan: a review of its use in migraine.
Keam SJ; Goa KL; Figgitt DP
Drugs; 2002; 62(2):387-414. PubMed ID: 11817980
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and safety of single escalating oral doses of eletriptan.
Shah AK; Harris SC; Greenhalgh C; Morganroth J
J Clin Pharmacol; 2002 May; 42(5):520-7. PubMed ID: 12017346
[TBL] [Abstract][Full Text] [Related]
15. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration.
Milton KA; Scott NR; Allen MJ; Abel S; Jenkins VC; James GC; Rance DJ; Eve MD
J Clin Pharmacol; 2002 May; 42(5):528-39. PubMed ID: 12017347
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.
van Marle S; van Vliet A; Sollie F; Kambayashi Y; Yamada-Sawada T
Int J Clin Pharmacol Ther; 2005 Jun; 43(6):282-93. PubMed ID: 15968885
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects.
Sharma A; Jusko WJ; Fulmor IE; Norton J; Uderman HD; Salazar DE
J Clin Pharmacol; 1999 Jul; 39(7):685-94. PubMed ID: 10392323
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.
Kunka RL; Hussey EK; Shaw S; Warner P; Aubert B; Richard I; Fowler PA; Pakes GE
Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
